Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells

Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells

Hepatocellular carcinoma (HCC) is one of the major causes of cancer-related deaths worldwide. Sorafenib has been used as a first-line systemic treatment for over a decade. However, resistance to sorafenib limits patient response and presents a major hurdle during HCC treatment. Lenvatinib has been a...

Full description

Bibliographic Details
Main Authors: Tingting Shi, Hisakazu Iwama, Koji Fujita, Hideki Kobara, Noriko Nishiyama, Shintaro Fujihara, Yasuhiro Goda, Hirohito Yoneyama, Asahiro Morishita, Joji Tani, Mari Yamada, Mai Nakahara, Kei Takuma, Tsutomu Masaki
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:International Journal of Molecular Sciences
Subjects:
lenvatinib
sorafenib-resistant
hepatocellular carcinoma
FGFR4
autophagy
microRNA
Online Access:https://www.mdpi.com/1422-0067/22/23/13071

Internet

https://www.mdpi.com/1422-0067/22/23/13071

Similar Items